PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
RVNC vs. HUM
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

RVNC vs. HUM

Last updated Jun 4, 2026

RVNC (Revance Therapeutics, Inc.) and HUM (Humana Inc.) are both stocks. Both are in the Healthcare sector — RVNC in Biotechnology, HUM in Healthcare Plans.

Performance

RVNC vs. HUM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Revance Therapeutics, Inc. (RVNC) and Humana Inc. (HUM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

RVNC

1D
0.00%
1M
0.00%
YTD
—
6M
—
1Y
—
3Y*
—
5Y*
—
10Y*
—

HUM

1D
2.08%
1M
37.64%
YTD
28.53%
6M
28.57%
1Y
42.54%
3Y*
-13.29%
5Y*
-4.20%
10Y*
6.70%
*Multi-year figures are annualized to reflect compound growth (CAGR)

RVNC vs. HUM - Yearly Performance Comparison

2026 (YTD)
RVNC
Revance Therapeutics, Inc.		0.00%
HUM
Humana Inc.		69.75%

Fundamentals

Total Revenue (TTM)

RVNC:

$247.00M

HUM:

$137.20B

Gross Profit (TTM)

RVNC:

$174.52M

HUM:

$13.28B

EBITDA (TTM)

RVNC:

-$150.16M

HUM:

$2.82B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Revance Therapeutics, Inc.

Humana Inc.

Often compared with RVNC:
RVNC vs. URARVNC vs. BIPCRVNC vs. SPYRVNC vs. CPBRVNC vs. TRVNC vs. ORLYRVNC vs. CVS
Often compared with HUM:
HUM vs. UNHHUM vs. CIHUM vs. CNCHUM vs. ^SP500TRHUM vs. ENSGHUM vs. IMBBYHUM vs. VOO

Return for Risk

RVNC vs. HUM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
RVNC
HUM
HUM Risk / Return Rank: 6363
Overall Rank
HUM Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
HUM Sortino Ratio Rank: 6262
Sortino Ratio Rank
HUM Omega Ratio Rank: 6666
Omega Ratio Rank
HUM Calmar Ratio Rank: 5959
Calmar Ratio Rank
HUM Martin Ratio Rank: 5959
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RVNC vs. HUM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Revance Therapeutics, Inc. (RVNC) and Humana Inc. (HUM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

RVNC vs. HUM - Sharpe Ratio Comparison

Loading charts...

Sharpe Ratios by Period

RVNCHUMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

—

0.87

—

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

—

-0.11

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.19

—

Sharpe Ratio (All Time)

Calculated using the full available price history

—

0.22

—

Drawdowns

RVNC vs. HUM - Drawdown Comparison

The maximum RVNC drawdown since its inception was 0.00%, smaller than the maximum HUM drawdown of -85.10%. Use the drawdown chart below to compare losses from any high point for RVNC and HUM.

Loading charts...

Drawdown Indicators

RVNCHUMDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-85.10%

+85.10%

Max Drawdown (1Y)

Largest decline over 1 year

—

-47.18%

—

Max Drawdown (3Y)

Largest decline over 3 years

—

-67.92%

—

Max Drawdown (5Y)

Largest decline over 5 years

—

-69.92%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-69.92%

—

Current Drawdown

Current decline from peak

0.00%

-39.49%

+39.49%

Average Drawdown

Average peak-to-trough decline

0.00%

-27.15%

+27.15%

Ulcer Index

Depth and duration of drawdowns from previous peaks

—

22.79%

—

Volatility

RVNC vs. HUM - Volatility Comparison

Loading charts...

Volatility by Period

RVNCHUMDifference

Volatility (1M)

Calculated over the trailing 1-month period

—

15.20%

—

Volatility (6M)

Calculated over the trailing 6-month period

—

38.83%

—

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

48.96%

-48.96%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

37.37%

-37.37%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

34.59%

-34.59%

Dividends

RVNC vs. HUM - Dividend Comparison

RVNC has not paid dividends to shareholders, while HUM's dividend yield for the trailing twelve months is around 1.08%.

PositionTTM20252024202320222021202020192018201720162015
HUM
Humana Inc.		1.08%1.38%1.40%0.77%0.62%0.60%0.61%0.60%0.70%0.76%0.43%0.64%
RVNC
Revance Therapeutics, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

RVNC vs. HUM - Financials Comparison

This section allows you to compare key financial metrics between Revance Therapeutics, Inc. and Humana Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.0010.00B20.00B30.00B40.00B20222023202420252026
59.88M
39.65B
(RVNC) Total Revenue
(HUM) Total Revenue
Values in USD except per share items
Portfolio Optimizer

Find the right allocation for RVNC and HUM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer